7/102 sources · 2 publishersUpdated Nov 4, 03:57 UTC
Ardelyx posts Q3 2026 revenue growth and reaffirms IBSRELA guidance
Ardelyx Inc. reported third‑quarter 2026 product revenue of $125.5 million, a 19% year‑over‑year increase, driven by IBSRELA sales of $96.3 million. The company reiterated its full‑year 2026 IBSRELA revenue guidance of $350 million‑$370 million and XPHOZAH guidance of $110 million‑$120 million. It also said it is targeting profitability in 2027 while expanding its pipeline.
Why it matters
The reaffirmed IBSRELA revenue range signals continued demand for the drug and supports the company’s growth outlook. Management’s 2027 profitability target may improve cash‑flow expectations for investors.
Key facts
- 1Q3 2026 total product revenue was $125.5 million, up from $105.5 million a year earlier. stocktitan.net
- 2Quarter‑over‑quarter revenue grew 19% year‑over‑year. stocktitan.net
- 3IBSRELA sales in Q3 2026 were $96.3 million, a 23% increase year‑over‑year. stocktitan.net
- 4Full‑year 2026 IBSRELA revenue guidance is $350 million‑$370 million. stocktitan.net
- 5Full‑year 2026 XPHOZAH revenue guidance is $110 million‑$120 million. stocktitan.net
- 6Cash, cash equivalents and short‑term investments totaled $285.3 million as of September 30, 2026. stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.